% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

ajetjock 7 posts  |  Last Activity: Jul 22, 2015 2:30 PM Member since: Mar 11, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Second Sight Just Quintupled Its Addressable Market
    Jim Collins Jim Collins , Contributor

    Second Sight just quintupled its addressable market.

    That’s not a typo. EYES announced this morning that the first patient of a five-patient trial in the U.K. focused on age-related macular degeneration had been implanted with the company’s Argus II retinal implant.

    By the company’s own calculations the global population of retinitis pigmentosa (RP) sufferers eligible for its Argus II “bionic eye” is 375,000. The eligible population of age-related macular degeneration (AMD) sufferers is 2 million.

    So, the implantation of an Argus II at the Manchester Royal Eye Hospital by Dr. Paulo Stanga is a transformational event for Second Sight. The study is aimed at the “dry” form of AMD, which is the more common of the two forms, representing about 85% of AMD sufferers worldwide. The BBC has a video about the experience.

    In Europe EYES’ Argus II is already indicated for patients with RP and AMD. Both are degenerative conditions. In RP the patient gradually loses peripheral vision until sight is completely lost, while in AMD central vision disappears first and then gradually spreads to the outer reaches of the visual field.

    There’s no reason, in my opinion, Argus II can’t be just as effective against AMD as it is versus RP, and the initial patient reaction (as shown in the BBC report) would indicate that is the case. I would heavily caution that this is just the initial patient response from a 5-patient trial, not a commercial sale, but the trial-to-test process should be quite fast. The company expects to begin marketing Argus II to AMD sufferers in Europe at some point in 2016 and the U.S. approval process will be greatly streamlined given the ability to transfer data gleaned from the Manchester study.

    Why? Because Argus II works. That’s the one question I receive the most from readers of my column–does Argus II really restore sight to the blind? Argu

    Sentiment: Strong Buy

  • Keep up the good work IPCI.

    Now think about an approval move up, starting at around 4 !

    Still LOW float and HIGH potential.

    Sentiment: Strong Buy

  • Reply to

    2015 ASCO Presentations

    by magnam_pi May 28, 2015 4:39 PM
    ajetjock ajetjock May 29, 2015 9:16 AM Flag

    Ya, seen that.

    Excellent exposure.

    Sentiment: Strong Buy

  • Fr yesterday's SA article:

    "Second Sight released record Q1 results which were generally in-line to my forecast for Q1.

    I maintain a $30 price target on EYES amid slight upward revisions to 2015-2018 estimates.

    EYES has a cash runway of 18-24 months, but has a billionaire supporter in Alfred Mann who would likely fund any future cash needs if not found elsewhere."

    " Q1 2015 revenue was a record $1.7 million, up 159% from Q1 2014 and up 12% from Q4 2014, the previous high point for revenue for the company. Gross margin was $0.4 million for the quarter, up 300% from $0.1 million achieved in Q4 2014. I reiterate my strong buy and $30 target on EYES as these results were close to my forecast and the conference call points to a bright future with the usual risks to be expected for a start up medical device company. "

    Sentiment: Strong Buy

  • Real investors KNOW that there are NO earnings for Bio-pharma at this stage of their life cycle.

    No one is looking for "earnings" at this stage. We are after a promising drug with FUTURE earnings potential.

    Sentiment: Strong Buy

  • ajetjock by ajetjock May 7, 2015 7:22 AM Flag

    Pivotal, Phase 3 GALAXY-2 Clinical Trial Remains on Track for Interim Analysis of Overall Survival in 2015. To date, over 500 patients have been enrolled in the GALAXY-2 trial, a Phase 3 global, randomized, multi-center study comparing the combination of ganetespib, the Companys lead program and a novel, potent small molecule inhibitor of heat shock protein 90 (Hsp90), and docetaxel to docetaxel alone for the second-line treatment of advanced non-small cell lung adenocarcinoma. The Company expects, based on current projections and statistical assumptions, that the first interim overall survival (OS) analysis of GALAXY-2 will be conducted in the second half of 2015, and the second interim and final OS analysis will be conducted in 2016. Assuming positive interim results from the ongoing GALAXY-2 trial of ganetespib, and pending regulatory feedback, the Company plans to seek regulatory approval of ganetespib in North America and Europe for NSCLC in 2016.

    Sentiment: Strong Buy

  • Reply to

    Serious Buys

    by eyegeewhiz Apr 30, 2015 4:51 PM
    ajetjock ajetjock May 1, 2015 7:21 AM Flag

    Well, there is a reason I (and SNTA insiders) never sold a share ...

    Sentiment: Strong Buy

2.139+0.039(+1.86%)2:48 PMEDT